Genetically enhancing the expression of chemokine domain of CX3CL1 fails to prevent tau pathology in mouse models of tauopathy

Shane M. Bemiller, Nicole M. Maphis, Shane V. Formica, Gina N. Wilson, Crystal M. Miller, Guixiang Xu, Olga N. Kokiko-Cochran, Ki Wook Kim, Steffen Jung, Judy L. Cannon, Samuel D. Crish, Astrid E. Cardona, Bruce Lamb, Kiran Bhaskar

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Fractalkine (CX3CL1) and its receptor (CX3CR1) play an important role in regulating microglial function. We have previously shown that Cx 3 cr1 deficiency exacerbated tau pathology and led to cognitive impairment. However, it is still unclear if the chemokine domain of the ligand CX3CL1 is essential in regulating neuronal tau pathology. Methods: We used transgenic mice lacking endogenous Cx 3 cl1 (Cx 3 cl1 -/-) and expressing only obligatory soluble form (with only chemokine domain) and lacking the mucin stalk of CX3CL1 (referred to as Cx 3 cl1 105Δ mice) to assess tau pathology and behavioral function in both lipopolysaccharide (LPS) and genetic (hTau) mouse models of tauopathy. Results: First, increased basal tau levels accompanied microglial activation in Cx 3 cl1 105Δ mice compared to control groups. Second, increased CD45+ and F4/80+ neuroinflammation and tau phosphorylation were observed in LPS, hTau/Cx 3 cl1 -/-, and hTau/Cx 3 cl1 105Δ mouse models of tau pathology, which correlated with impaired spatial learning. Finally, microglial cell surface expression of CX3CR1 was reduced in Cx 3 cl1 105Δ mice, suggesting enhanced fractalkine receptor internalization (mimicking Cx 3 cr1 deletion), which likely contributes to the elevated tau pathology. Conclusions: Collectively, our data suggest that overexpression of only chemokine domain of CX3CL1 does not protect against tau pathology.

Original languageEnglish (US)
Article number278
JournalJournal of Neuroinflammation
Volume15
Issue number1
DOIs
StatePublished - Sep 25 2018

Fingerprint

Chemokine CX3CL1
Tauopathies
Pathology
Chemokines
Lipopolysaccharides
Mucins
Transgenic Mice
Phosphorylation
Ligands
Control Groups

Keywords

  • Alzheimer's disease
  • CXCL1
  • CXCR1
  • Microglia
  • Neuroinflammation
  • Tau
  • Tauopathies

ASJC Scopus subject areas

  • Neuroscience(all)
  • Immunology
  • Neurology
  • Cellular and Molecular Neuroscience

Cite this

Genetically enhancing the expression of chemokine domain of CX3CL1 fails to prevent tau pathology in mouse models of tauopathy. / Bemiller, Shane M.; Maphis, Nicole M.; Formica, Shane V.; Wilson, Gina N.; Miller, Crystal M.; Xu, Guixiang; Kokiko-Cochran, Olga N.; Kim, Ki Wook; Jung, Steffen; Cannon, Judy L.; Crish, Samuel D.; Cardona, Astrid E.; Lamb, Bruce; Bhaskar, Kiran.

In: Journal of Neuroinflammation, Vol. 15, No. 1, 278, 25.09.2018.

Research output: Contribution to journalArticle

Bemiller, SM, Maphis, NM, Formica, SV, Wilson, GN, Miller, CM, Xu, G, Kokiko-Cochran, ON, Kim, KW, Jung, S, Cannon, JL, Crish, SD, Cardona, AE, Lamb, B & Bhaskar, K 2018, 'Genetically enhancing the expression of chemokine domain of CX3CL1 fails to prevent tau pathology in mouse models of tauopathy', Journal of Neuroinflammation, vol. 15, no. 1, 278. https://doi.org/10.1186/s12974-018-1310-6
Bemiller, Shane M. ; Maphis, Nicole M. ; Formica, Shane V. ; Wilson, Gina N. ; Miller, Crystal M. ; Xu, Guixiang ; Kokiko-Cochran, Olga N. ; Kim, Ki Wook ; Jung, Steffen ; Cannon, Judy L. ; Crish, Samuel D. ; Cardona, Astrid E. ; Lamb, Bruce ; Bhaskar, Kiran. / Genetically enhancing the expression of chemokine domain of CX3CL1 fails to prevent tau pathology in mouse models of tauopathy. In: Journal of Neuroinflammation. 2018 ; Vol. 15, No. 1.
@article{2d4fd3f7bbfe4c688c374162d612ff5b,
title = "Genetically enhancing the expression of chemokine domain of CX3CL1 fails to prevent tau pathology in mouse models of tauopathy",
abstract = "Background: Fractalkine (CX3CL1) and its receptor (CX3CR1) play an important role in regulating microglial function. We have previously shown that Cx 3 cr1 deficiency exacerbated tau pathology and led to cognitive impairment. However, it is still unclear if the chemokine domain of the ligand CX3CL1 is essential in regulating neuronal tau pathology. Methods: We used transgenic mice lacking endogenous Cx 3 cl1 (Cx 3 cl1 -/-) and expressing only obligatory soluble form (with only chemokine domain) and lacking the mucin stalk of CX3CL1 (referred to as Cx 3 cl1 105Δ mice) to assess tau pathology and behavioral function in both lipopolysaccharide (LPS) and genetic (hTau) mouse models of tauopathy. Results: First, increased basal tau levels accompanied microglial activation in Cx 3 cl1 105Δ mice compared to control groups. Second, increased CD45+ and F4/80+ neuroinflammation and tau phosphorylation were observed in LPS, hTau/Cx 3 cl1 -/-, and hTau/Cx 3 cl1 105Δ mouse models of tau pathology, which correlated with impaired spatial learning. Finally, microglial cell surface expression of CX3CR1 was reduced in Cx 3 cl1 105Δ mice, suggesting enhanced fractalkine receptor internalization (mimicking Cx 3 cr1 deletion), which likely contributes to the elevated tau pathology. Conclusions: Collectively, our data suggest that overexpression of only chemokine domain of CX3CL1 does not protect against tau pathology.",
keywords = "Alzheimer's disease, CXCL1, CXCR1, Microglia, Neuroinflammation, Tau, Tauopathies",
author = "Bemiller, {Shane M.} and Maphis, {Nicole M.} and Formica, {Shane V.} and Wilson, {Gina N.} and Miller, {Crystal M.} and Guixiang Xu and Kokiko-Cochran, {Olga N.} and Kim, {Ki Wook} and Steffen Jung and Cannon, {Judy L.} and Crish, {Samuel D.} and Cardona, {Astrid E.} and Bruce Lamb and Kiran Bhaskar",
year = "2018",
month = "9",
day = "25",
doi = "10.1186/s12974-018-1310-6",
language = "English (US)",
volume = "15",
journal = "Journal of Neuroinflammation",
issn = "1742-2094",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Genetically enhancing the expression of chemokine domain of CX3CL1 fails to prevent tau pathology in mouse models of tauopathy

AU - Bemiller, Shane M.

AU - Maphis, Nicole M.

AU - Formica, Shane V.

AU - Wilson, Gina N.

AU - Miller, Crystal M.

AU - Xu, Guixiang

AU - Kokiko-Cochran, Olga N.

AU - Kim, Ki Wook

AU - Jung, Steffen

AU - Cannon, Judy L.

AU - Crish, Samuel D.

AU - Cardona, Astrid E.

AU - Lamb, Bruce

AU - Bhaskar, Kiran

PY - 2018/9/25

Y1 - 2018/9/25

N2 - Background: Fractalkine (CX3CL1) and its receptor (CX3CR1) play an important role in regulating microglial function. We have previously shown that Cx 3 cr1 deficiency exacerbated tau pathology and led to cognitive impairment. However, it is still unclear if the chemokine domain of the ligand CX3CL1 is essential in regulating neuronal tau pathology. Methods: We used transgenic mice lacking endogenous Cx 3 cl1 (Cx 3 cl1 -/-) and expressing only obligatory soluble form (with only chemokine domain) and lacking the mucin stalk of CX3CL1 (referred to as Cx 3 cl1 105Δ mice) to assess tau pathology and behavioral function in both lipopolysaccharide (LPS) and genetic (hTau) mouse models of tauopathy. Results: First, increased basal tau levels accompanied microglial activation in Cx 3 cl1 105Δ mice compared to control groups. Second, increased CD45+ and F4/80+ neuroinflammation and tau phosphorylation were observed in LPS, hTau/Cx 3 cl1 -/-, and hTau/Cx 3 cl1 105Δ mouse models of tau pathology, which correlated with impaired spatial learning. Finally, microglial cell surface expression of CX3CR1 was reduced in Cx 3 cl1 105Δ mice, suggesting enhanced fractalkine receptor internalization (mimicking Cx 3 cr1 deletion), which likely contributes to the elevated tau pathology. Conclusions: Collectively, our data suggest that overexpression of only chemokine domain of CX3CL1 does not protect against tau pathology.

AB - Background: Fractalkine (CX3CL1) and its receptor (CX3CR1) play an important role in regulating microglial function. We have previously shown that Cx 3 cr1 deficiency exacerbated tau pathology and led to cognitive impairment. However, it is still unclear if the chemokine domain of the ligand CX3CL1 is essential in regulating neuronal tau pathology. Methods: We used transgenic mice lacking endogenous Cx 3 cl1 (Cx 3 cl1 -/-) and expressing only obligatory soluble form (with only chemokine domain) and lacking the mucin stalk of CX3CL1 (referred to as Cx 3 cl1 105Δ mice) to assess tau pathology and behavioral function in both lipopolysaccharide (LPS) and genetic (hTau) mouse models of tauopathy. Results: First, increased basal tau levels accompanied microglial activation in Cx 3 cl1 105Δ mice compared to control groups. Second, increased CD45+ and F4/80+ neuroinflammation and tau phosphorylation were observed in LPS, hTau/Cx 3 cl1 -/-, and hTau/Cx 3 cl1 105Δ mouse models of tau pathology, which correlated with impaired spatial learning. Finally, microglial cell surface expression of CX3CR1 was reduced in Cx 3 cl1 105Δ mice, suggesting enhanced fractalkine receptor internalization (mimicking Cx 3 cr1 deletion), which likely contributes to the elevated tau pathology. Conclusions: Collectively, our data suggest that overexpression of only chemokine domain of CX3CL1 does not protect against tau pathology.

KW - Alzheimer's disease

KW - CXCL1

KW - CXCR1

KW - Microglia

KW - Neuroinflammation

KW - Tau

KW - Tauopathies

UR - http://www.scopus.com/inward/record.url?scp=85054026297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054026297&partnerID=8YFLogxK

U2 - 10.1186/s12974-018-1310-6

DO - 10.1186/s12974-018-1310-6

M3 - Article

VL - 15

JO - Journal of Neuroinflammation

JF - Journal of Neuroinflammation

SN - 1742-2094

IS - 1

M1 - 278

ER -